Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
← catalyst calendarNCT03567889 · readout ≤ 499 d
Sponsored by Philogen S.p.A. (industry) · PHIL.MI — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
186estimated
Sites
37
Countries
Spain, Switzerland, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-09-20 | actual | When the study began enrolling |
| Primary completion | Dec 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2018-06-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Melanoma Stage IIIB
- Melanoma Stage IIIC
- Melanoma Stage IIID
Interventions
- Drug: Daromun
- Procedure: Surgery
- Drug: Adjuvant therapy
Primary outcome
what the primary-completion date above is the date OFRecurrence Free Survival (RFS)
measured From date of randomization until the date of the first recurrence or date of death from any cause, whichever occurs first assessed up to 60 months.
Publications
- PMID 36648215 — linked by the registry
- PMID 31538818 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · PHIL.MI's whole pipeline · Catalyst calendar · Every registered study · What changed